Dr. Kathy S. Albain on Breast Cancer Risk After 5 Years of Tamoxifen

Kathy S. Albain, MD
Published: Wednesday, Aug 31, 2016


Kathy S. Albain, MD, hematology/oncology, professor, Loyola University Chicago Stritch School of Medicine, discusses risk 5 years after tamoxifen in early stage ER-positive breast cancer.
 
Data was recently reported emphasizing that after patients stop 5 years of tamoxifen in early breast cancer, even if they have low-stage disease, there is a long-term recurrence rate out to 20 years, says Albain.
 
For the lowest stage, T1N0, the risk is 14%. The risk goes up incrementally as the number of nodes and the tumor size increases. There is a six-point scoring system that shows the gradations of increased risk across each stage of disease.
 
These data are very important as oncologists counsel women coming off 5 years of tamoxifen regarding their continued risk of recurrence.
 

Kathy S. Albain, MD, hematology/oncology, professor, Loyola University Chicago Stritch School of Medicine, discusses risk 5 years after tamoxifen in early stage ER-positive breast cancer.
 
Data was recently reported emphasizing that after patients stop 5 years of tamoxifen in early breast cancer, even if they have low-stage disease, there is a long-term recurrence rate out to 20 years, says Albain.
 
For the lowest stage, T1N0, the risk is 14%. The risk goes up incrementally as the number of nodes and the tumor size increases. There is a six-point scoring system that shows the gradations of increased risk across each stage of disease.
 
These data are very important as oncologists counsel women coming off 5 years of tamoxifen regarding their continued risk of recurrence.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 16th Annual International Congress on the Future of Breast Cancer®Sep 29, 20182.0
School of Breast Oncology®: Mid-Year Video Update OnlineSep 30, 20182.0
Publication Bottom Border
Border Publication
x